comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 04:53:01 Page View：251

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： First recipient of genetically engineered pig kidney has died
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

focus

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Readout LOUD podcast: What to know about H5N1 bird flu

Whathappenswhenacommonvirusjumpsfrombirdstocows?Andshouldwebeconcerned?Thisweekon“TheReadoutLOUD,”ST

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Use wet bulb globe temperature, not heat index, to protect workers

FarmworkerspickinggrapesinCalifornia'sCentralValleyduringthe2021heatwave.FREDERICJ.BROWN/AFPviaGetty

comprehensive

explore

focus

Use wet bulb globe temperature, not heat index, to protect workers